Trial reportImmunology2022
Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers.
Trial report in Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Trial
- Modelling innate and adaptive immune responses in whole blood: A modifiedJournal of biological methods · 2025Article
- Comparison of different T cell assays for the retrospective determination of SARS-CoV-2 infection.The Journal of general virology · 2024Article
- A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation.NPJ vaccines · 2024Article
- Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T.International journal of hematology · 2023Review
- SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants.Pathogens (Basel, Switzerland) · 2023Review
- Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients.Frontiers in immunology · 2023Article
- Article
- Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity.Nature communications · 2022Article
- Evaluation of the shielding initiative in Wales (EVITE Immunity): protocol for a quasiexperimental study.BMJ open · 2022Article
- SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination.European journal of immunology · 2022Article
- Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID.EBioMedicine · 2022Article
- Healthy Immunity on Preventive Medicine for Combating COVID-19.Nutrients · 2022Review
- Oncofertility and COVID-19: At the Crossroads between Two Time-Sensitive Fields.Journal of clinical medicine · 2022Review
- COVID-19 and its genomic variants: Molecular pathogenesis and therapeutic interventions.EXCLI journal · 2022Review
- Adaptive Immune Responses and Immunity to SARS-CoV-2.Frontiers in immunology · 2022Review
- T cells in SARS-CoV-2 infection and vaccination.Therapeutic advances in vaccines and immunotherapy · 2022Review
- COVID-19 Vaccine Response in People with Multiple Sclerosis.Annals of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 3 countries.
Funding
Abstract
Accurate assessment of SARS-CoV-2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS-CoV-2-specific T-cell responses are a critical feature that will likely form a key correlate of protection against COVID-19. Here, we developed and optimized a high-throughput whole blood-based assay to determine the T-cell response associated with prior SARS-CoV-2 infection and/or vaccination amongst 231 healthy donors and 68 cancer patients. Following overnight in vitro stimulation with SARS-CoV-2-specific peptides, blood plasma samples were analysed for T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.